Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Only PARP inhibitor to improve overall survival versus new hormonal treatments in advanced prostate cancer First PARP inhibitor approved in China in advanced prostate cancerAstraZeneca and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment that included a new hormonal agent (abiraterone, enzalutamide). In China, prostate cancer is the sixth most prevalent cancer in men, with approximately 115,000 new